Home LiteratureArticle Details
PMID: 10220543 Published · ppublish English Comparative Study Journal Article

Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men.

Heart (British Cardiac Society) ·Vol. 81 ·No. 1 ·1999-01-00 ·Pages 40-6

Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ

Abstract

To examine the validity of estimates of coronary heart disease (CHD) risk by the Framingham risk function, for European populations. Comparison of CHD risk estimates for individuals derived from the Framingham, prospective cardiovascular Münster (PROCAM), Dundee, and British regional heart (BRHS) risk functions. Sheffield Hypertension Clinic. Patients-206 consecutive hypertensive men aged 35-75 years without preexisting vascular disease. There was close agreement among the Framingham, PROCAM, and Dundee risk functions for average CHD risk. For individuals the best correlation was between Framingham and PROCAM, both of which use high density lipoprotein (HDL) cholesterol. When Framingham was used to target a CHD event rate > 3% per year, it identified men with mean CHD risk by PROCAM of 4.6% per year and all had CHD event risks > 1.5% per year. Men at lower risk by Framingham had a mean CHD risk by PROCAM of 1.5% per year, with 16% having a CHD event risk > 3.0% per year. BRHS risk function estimates of CHD risk were fourfold lower than those for the other three risk functions, but with moderate correlations, suggesting an important systematic error. There is close agreement between the Framingham, PROCAM, and Dundee risk functions as regards average CHD risk, and moderate agreement for estimates within individuals. Taking PROCAM as the external standard, the Framingham function separates high and low CHD risk groups and is acceptably accurate for northern European populations, at least in men.

MeSH Terms
Adult Aged Coronary Disease/complications,ethnology,prevention & control Europe/ethnology Humans Hypertension/complications,ethnology Logistic Models Male Middle Aged Predictive Value of Tests Risk Factors Surveys and Questionnaires
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Haq I U
Section of Clinical Pharmacology and Therapeutics, Department of Medicine and Pharmacology, University of Sheffield, Sheffield, UK.
Ramsay L E
Yeo W W
Jackson P R
Wallis E J
References (26)
26 references, click to expand
  1. Probability of middle-aged men developing coronary heart disease in five years.
    Circulation. 1972 Apr;45(4):815-28 PMID: 5016014
  2. Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence?
    J Hypertens Suppl. 1996 Dec;14(5):S187-94 PMID: 9120677
  3. Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico.
    J Chronic Dis. 1974 Sep;27(7-8):329-44 PMID: 4436425
  4. Multivariate prediction of coronary heart disease in the Western Collaborative Group Study compared to the findings of the Framingham study.
    Circulation. 1976 Feb;53(2):348-55 PMID: 1245042
  5. Weight and mortality in the Whitehall Study.
    Br Med J (Clin Res Ed). 1982 Aug 21;285(6341):535-7 PMID: 6809160
  6. UK heart disease prevention project: incidence and mortality results.
    Lancet. 1983 May 14;1(8333):1062-6 PMID: 6133103
  7. The seven countries study: 2,289 deaths in 15 years.
    Prev Med. 1984 Mar;13(2):141-54 PMID: 6739443
  8. Statistical methods for assessing agreement between two methods of clinical measurement.
    Lancet. 1986 Feb 8;1(8476):307-10 PMID: 2868172
  9. Identifying men at high risk of heart attacks: strategy for use in general practice.
    Br Med J (Clin Res Ed). 1986 Aug 23;293(6545):474-9 PMID: 3091165
  10. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study.
    J Chronic Dis. 1987;40(8):775-84 PMID: 3597679
  11. On the use of a logistic risk score in predicting risk of coronary heart disease.
    Stat Med. 1990 Apr;9(4):385-96 PMID: 2362977
  12. Cardiovascular disease risk profiles.
    Am Heart J. 1991 Jan;121(1 Pt 2):293-8 PMID: 1985385
  13. Management of raised blood pressure in New Zealand: a discussion document.
    BMJ. 1993 Jul 10;307(6896):107-10 PMID: 8343706
  14. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.
    Eur Heart J. 1994 Oct;15(10):1300-31 PMID: 7821306
  15. The number needed to treat: a clinically useful measure of treatment effect.
    BMJ. 1995 Feb 18;310(6977):452-4 PMID: 7873954
  16. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study.
    BMJ. 1995 Apr 15;310(6985):975-8 PMID: 7728035
  17. Estimation of CHD risk in a French working population using a modified Framingham model. The PCV-METRA Group.
    J Clin Epidemiol. 1994 Dec;47(12):1353-64 PMID: 7730844
  18. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?
    JAMA. 1995 Sep 13;274(10):801-6 PMID: 7650803
  19. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
    N Engl J Med. 1995 Nov 16;333(20):1301-7 PMID: 7566020
  20. The cost effectiveness of hypertension treatment in Sweden.
    Pharmacoeconomics. 1995 Mar;7(3):242-50 PMID: 10155314
  21. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease.
    Lancet. 1995 Dec 2;346(8988):1467-71 PMID: 7490996
  22. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table.
    Lancet. 1996 Aug 10;348(9024):387-8 PMID: 8709740
  23. Using a coronary risk score for screening and intervention in general practice. British Family Heart Study.
    J Cardiovasc Risk. 1996 Jun;3(3):301-6 PMID: 8863103
  24. The Sheffield table for primary prevention of coronary heart disease: corrected.
    Lancet. 1996 Nov 2;348(9036):1251 PMID: 8898071
  25. Lipid-lowering for prevention of coronary heart disease: what policy now?
    Clin Sci (Lond). 1996 Oct;91(4):399-413 PMID: 8983865
  26. Information needed to decide about cardiovascular treatment in primary care.
    BMJ. 1997 Jan 25;314(7076):277-80 PMID: 9022493
Article Info
Journal
Heart (British Cardiac Society)
Abbr.
Heart
ISSN
1355-6037
Published
1999-01-00
Pages
40-6
Language
English
Region
England
NLM ID
9602087
PMCID
PMC1728900
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]